tiprankstipranks
Astellas Pharma Revises 2024 Financial Forecast Amid Core Business Growth and Impairment Losses
Company Announcements

Astellas Pharma Revises 2024 Financial Forecast Amid Core Business Growth and Impairment Losses

Story Highlights

Invest with Confidence:

Astellas Pharma ( (JP:4503) ) just unveiled an announcement.

Astellas Pharma has revised its financial forecasts for fiscal year 2024, driven by the expansion of XTANDI™ sales in the U.S. and favorable foreign exchange impacts that are anticipated to boost revenue and profit. However, the company will incur significant impairment losses due to the withdrawal of a marketing application for IZERVAY™ in Europe, updates to its gene therapy program, and the discontinuation of certain projects, leading to a revised financial outlook with increased revenue but decreased profit figures on a full basis.

More about Astellas Pharma

Astellas Pharma Inc. is a Japanese pharmaceutical company that focuses on the development and sales of innovative medicines, primarily in the areas of oncology, urology, immunology, nephrology, and neuroscience. The company is known for its product XTANDI™, used in the treatment of prostate cancer, and is strategically expanding its market presence in the United States.

YTD Price Performance: -2.54%

Average Trading Volume: 4,705

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $17.21B

For an in-depth examination of 4503 stock, go to TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles